VOLOPEM Film-coated Tablet

Bosutinib
500 mg
The Arab Pharmaceutical Manufacturing PSC
Pack size 28's Pack
Dispensing mode
Source
Agent
Retail Price 322.51 AED

Indications

VOLOPEM Film-coated Tablet is used for: Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.

Adult Dose

Child Dose

Renal Dose

Administration

Contra Indications

Precautions

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Bosutinib :

Mechanism of Action

Bosutinib is a tyrosine kinase inhibitor. Although it is able to inhibit several tyrosine kinases such as Src, Lyn, and Hck, which are members of the Src-family of kinases, its primary target is the Bcr-Abl kinase. The Bcr-Abl gene is a chimeric oncogene created from the fusion of the breakpoint-cluster (Bcr) gene and Abelson (Abl) tyrosine gene. This chromosomal abnormality results in the formation of what is commonly known as the Philadelphia chromosome or Philadelphia translocation. The Bcr-Abl gene expresses a particular kinase that promotes the progression of CML. A decrease in the growth and size of the CML tumour has been observed following administration of bosutinib. Bosutinib did not inhibit the T315I and V299L mutant cells.

Note

VOLOPEM 500 mg Film-coated Tablet manufactured by The Arab Pharmaceutical Manufacturing PSC. Its generic name is Bosutinib. VOLOPEM is availble in Saudi Arabia. Farmaco SA drug index information on VOLOPEM Film-coated Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Bosutinib :